STAR: A randomised multiStage phase II/III trial of Standard first-line therapy (sunitinib or pazopanib) comparing Temporary cessation with Allowing continuation, in the firstline treatment of locally advanced and/or metastatic Renal cancer

Trial Profile

STAR: A randomised multiStage phase II/III trial of Standard first-line therapy (sunitinib or pazopanib) comparing Temporary cessation with Allowing continuation, in the firstline treatment of locally advanced and/or metastatic Renal cancer

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Pazopanib (Primary) ; Sunitinib (Primary)
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Acronyms STAR
  • Most Recent Events

    • 17 Dec 2015 Accrual to date is 54% according to the United Kingdom Clinical Research Network record.
    • 04 Nov 2015 Accrual to date is 50% according to the United Kingdom Clinical Research Network record.
    • 05 Oct 2015 Accrual to date is 48% according to the United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top